SIRPα antagonist
SIRPα antagonist
Search
Boehringer founding sponsor of CKM Health Initiative
Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative
Access to Healthcare Strategy Innovation
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
Dominik Huber
Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Animal Health Innovation
Animal Health Innovation
Digital innovation: „We change the way labs work“
QUDA – an in-house software – changes the way labs work. It increases our quality assurance and our drug saftey.
Veronika Kohlbrenner
Veronika Kohlbrenner, Patient Safety Physician in Therapeutic Area Inflammation, tells us how she is able to work across different levels of the drug development process.
Rafał Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in our Global Business Service (GBS) Center in Wroclaw, looks back on a bustling beginning with Boehringer Ingelheim – for him and the Center alike.
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Corporate Strategy & Consulting
Corporate Strategy & Consulting
H5N1: Bird flu again. What’s different now?
H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.
Boosting performance with an inclusive performance culture
Boosting performance of organizations with an inclusive performance culture
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Patient Centricity
Patient Centricity
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Heart Diseases in humans and animals
Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
Early Careers
Early Careers
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Upstream and Downstream Processing | Bioxcellence | Boehringer Ingelheim
Experience our exceptional expertise in upstream & downstream biopharmaceutical processing, utilizing mammalian cell cultures & microbial organisms.
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
Generalized pustular psoriasis: Value of community support
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.